ResMed Payments for Repurchase of Common Stock decreased by 0.0% to $175.01M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 133.3%, from $75.03M to $175.01M. This is a positive signal — lower values indicate better performance for this metric.
Higher spending indicates a commitment to returning capital to shareholders or offsetting dilution from stock-based compensation.
The cash outflow associated with the company's repurchase of its own common shares from the open market. This is a prima...
Standard capital return metric for mature public companies.
other_payments_for_repurchase_of_common_stock| Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $50.01M | $50.00M | $50.00M | $50.01M | $74.99M | $75.03M | $100.01M | $150.01M | $175.01M | $175.01M |
| QoQ Change | — | — | — | — | — | — | — | — | — | — | -0.0% | +0.0% | +0.0% | +50.0% | +0.1% | +33.3% | +50.0% | +16.7% | -0.0% |
| YoY Change | — | — | — | — | — | — | — | — | — | — | — | — | — | +50.0% | +50.1% | +100.0% | +200.0% | +133.4% | +133.3% |